ABD - İngilizce - NLM (National Library of Medicine)

meda pharmaceuticals - azelastine hydrochloride (unii: 0l591qr10i) (azelastine - unii:zqi909440x) - astelin nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older. none. limited data from postmarketing experience over decades of use with astelin in pregnant women have not identified any drug associated risks of miscarriage, birth defects, or other adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm at oral doses approximately 5 times the clinical daily dose.  oral administration of azelastine hydrochloride to pregnant mice, rats, and rabbits, during the period of organogenesis, produced developmental toxicity that included structural abnormalities, decreased embryo-fetal survival, and decreased fetal body weights at doses 270 times and higher than the maximum recommended human daily intranasal dose (mrhdid) of 1.096 mg. however, the relevance of these findings

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; polysorbate 80; microcrystalline cellulose; pregelatinised maize starch - antineoplastic chemotherapy: treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy: (see warnings box and precautions). because of the high risk attending to its use, methoblastin is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatolo

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; maize starch; polysorbate 80; microcrystalline cellulose; magnesium stearate - treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy: (see warnings box and precautions). because of the high risk attending to its use, methoblastin is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultations. rheumatoid

İsrail - İngilizce - Ministry of Health

rafa laboratories ltd - bilastine - tablets - bilastine 20 mg - bilastine - bilaxten is indicated for the symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticariai in adults and adolescents (12 years of age and over).

Belçika - İngilizce - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bilastine monohydrate 20,776 mg - eq. bilastine 20 mg - tablet - bilastine

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vinblastine sulfate 1 mg/ml - solution for injection - 1 mg/ml - active: vinblastine sulfate 1 mg/ml excipient: sodium chloride sodium hydroxide sulfuric acid water for injection

Malta - İngilizce - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - vinblastine sulfate - solution for injection - vinblastine sulfate 1 mg/ml - antineoplastic agents

Kanada - İngilizce - Health Canada

david bull laboratories (pty) ltd. - vinblastine sulfate - liquid - 1mg - vinblastine sulfate 1mg - antineoplastic agents

Malta - İngilizce - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - vinblastine sulfate - solution for injection/infusion - vinblastine sulfate 1 mg/ml - antineoplastic agents

Malta - İngilizce - Medicines Authority

meda pharmaceuticals limited - azelastine hydrochloride; fluticasone propionate - nasal spray, suspension - azelastine hydrochloride 137 µg; fluticasone propionate 50 µg - nasal preparations